TLDR: Global healthcare private equity firm ARCHIMED has acquired a majority stake in Arkstone Medical Solutions, a Florida-based biotechnology company specializing in generative AI and machine learning for infectious disease diagnostics. This acquisition aims to accelerate the global deployment of Arkstone’s OneChoice Report, an AI-driven tool that provides optimal treatment recommendations and supports the fight against antimicrobial resistance.
ARCHIMED, a prominent global healthcare private equity firm, has announced its acquisition of a majority stake in Arkstone Medical Solutions, a pioneering biotechnology company based in Florida. The strategic move, finalized around late July/early August 2025, is set to significantly bolster the fight against infectious diseases and antimicrobial resistance (AMR) through advanced artificial intelligence.
Arkstone Medical Solutions, founded in 2018 by a team with expertise in software, clinical content, and customer operations, has distinguished itself in the field of infectious disease clinical guidance and antimicrobial stewardship. The company leverages cutting-edge machine learning (ML) and generative artificial intelligence (gen AI) to provide crucial clinical decision support, helping healthcare providers optimize antimicrobial usage.
At the core of Arkstone’s innovation is its flagship product, the OneChoice Report. This sophisticated tool utilizes ML and gen AI to analyze laboratory results alongside comprehensive patient data, delivering precise, optimal infectious disease treatment recommendations directly to clinicians. This capability is vital in ensuring appropriate antibiotic prescriptions, thereby combating the growing threat of antimicrobial resistance.
Currently, Arkstone’s technology is deployed in over 150 laboratories across the United States and internationally, demonstrating its established impact on how healthcare providers diagnose, treat, and understand infectious diseases. The acquisition by ARCHIMED is expected to accelerate Arkstone’s global expansion, deepen its research and development capabilities, and make its precision-guided technology accessible to a wider network of clinicians worldwide.
Igor Petricca, a Partner at ARCHIMED, emphasized the significance of this partnership, stating, “Arkstone’s OneChoice Report is redefining infectious disease management. Our partnership will enable Arkstone to reach more markets, accelerate product innovation, and ultimately save lives by reducing the misuse of antibiotics.” Petricca further highlighted the strategic alignment, noting that the deal sits at the “crossroads of hot subsectors of our Healthcare IT and Diagnostics franchises.”
Also Read:
- Abridge Secures $300 Million in Series E Funding to Advance AI-Powered Medical Documentation
- AVANT BIO and Intrepid Labs Secure Esteemed Prix Galien USA Award Nominations
While the financial terms of the acquisition were not disclosed, the partnership underscores ARCHIMED’s commitment to investing in innovative healthcare solutions that address critical public health challenges. Arkstone will continue to operate with its existing team, ensuring continuity and leveraging ARCHIMED’s capital, extensive healthcare expertise, and international reach to scale its impact on global health.
